Literature DB >> 20559776

Delivery of gene and cellular therapies for heart disease.

Justin A Mariani1, David M Kaye.   

Abstract

Although there has been considerable interest in the utilization of gene and cellular therapy for heart disease in recent years, there remain critical questions prior to widespread promotion of therapy, and key among these issues is the delivery method used for both gene therapy and cellular therapy. Much of the failure of gene and cellular therapy can be explained by the biological therapy itself; however, certainly there is a critical role played by the delivery technique, in particular, those that have been adapted from routine clinical use such as intravenous and intracoronary injection. Development of novel techniques to deliver gene and cellular therapy has ensued with some preclinical and even clinical success, though questions regarding safety, invasiveness, and repeatability remain. Here, we review techniques for gene and cellular therapy delivery, both existing and adapted techniques, and novel techniques that have emerged recently at promoting improved efficacy of therapy without the cost of systemic distribution. We also highlight key issues that need to be addressed to improve the chances of success of delivery techniques to enhance therapeutic benefit.

Entities:  

Mesh:

Year:  2010        PMID: 20559776     DOI: 10.1007/s12265-010-9190-x

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  84 in total

Review 1.  Intrapericardial therapeutics and diagnostics.

Authors:  D H Spodick
Journal:  Am J Cardiol       Date:  2000-04-15       Impact factor: 2.778

2.  Cardiac gene delivery with cardiopulmonary bypass.

Authors:  M J Davidson; J M Jones; S M Emani; K H Wilson; J Jaggers; W J Koch; C A Milano
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

3.  Intracoronary delivery of hematopoietic bone marrow stem cells and luminal loss of the infarct-related artery in patients with recent myocardial infarction.

Authors:  Samer Mansour; Marc Vanderheyden; Bernard De Bruyne; Bart Vandekerckhove; Leen Delrue; Inge Van Haute; Guy Heyndrickx; Stephane Carlier; Gaston Rodriguez-Granillo; William Wijns; Jozef Bartunek
Journal:  J Am Coll Cardiol       Date:  2006-03-27       Impact factor: 24.094

4.  Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Nikos Werner; Jürgen Haase; Jörg Neuzner; Alfried Germing; Bernd Mark; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Eur Heart J       Date:  2006-11-10       Impact factor: 29.983

5.  Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution.

Authors:  Alain Bel; Emmanuel Messas; Onnik Agbulut; Patrice Richard; Jane-Lyse Samuel; Patrick Bruneval; Albert A Hagège; Philippe Menasché
Journal:  Circulation       Date:  2003-09-09       Impact factor: 29.690

6.  Intracoronary delivery of bone marrow cells to the acutely infarcted myocardium. Optimization of the delivery technique.

Authors:  Jaroslav Meluzín; Michal Vlasín; Ladislav Groch; Jirí Mayer; Leos Kren; Petr Rauser; Boris Tichý; Ivan Hornácek; Jan Sitar; Stanislav Palsa; Martin Klabusay; Zdenek Korístek; Michael Doubek; Sárka Pospísilová; Leona Lexmaulová; Ladislav Dusek
Journal:  Cardiology       Date:  2008-06-27       Impact factor: 1.869

7.  Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia.

Authors:  Georges von Degenfeld; Philip Raake; Christian Kupatt; Corinna Lebherz; Rabea Hinkel; Franz Josef Gildehaus; Wolfgang Münzing; Andrea Kranz; Johannes Waltenberger; Marcus Simoes; Markus Schwaiger; Eckart Thein; Peter Boekstegers
Journal:  J Am Coll Cardiol       Date:  2003-09-17       Impact factor: 24.094

8.  Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

Authors:  Douglas W Losordo; Richard A Schatz; Christopher J White; James E Udelson; Vimal Veereshwarayya; Michelle Durgin; Kian Keong Poh; Robert Weinstein; Marianne Kearney; Muqtada Chaudhry; Aaron Burg; Liz Eaton; Lindsay Heyd; Tina Thorne; Leon Shturman; Peter Hoffmeister; Ken Story; Victor Zak; Douglas Dowling; Jay H Traverse; Rachel E Olson; Janice Flanagan; Donata Sodano; Toshinori Murayama; Atsuhiko Kawamoto; Kengo Fukushima Kusano; Jill Wollins; Frederick Welt; Pinak Shah; Peter Soukas; Takayuki Asahara; Timothy D Henry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

Review 9.  Cardiac resynchronisation therapy for heart failure.

Authors:  J A Mariani; P A Gould; A Broughton; D M Kaye
Journal:  Intern Med J       Date:  2006-02       Impact factor: 2.048

10.  Cardiac-specific gene expression facilitated by an enhanced myosin light chain promoter.

Authors:  Wolfgang Boecker; Oliver Y Bernecker; Joseph C Wu; Xinsheng Zhu; Tomohiro Sawa; Luanda Grazette; Anthony Rosenzweig; Federica del Monte; Ulrich Schmidt; Roger J Hajjar
Journal:  Mol Imaging       Date:  2004-04       Impact factor: 4.488

View more
  3 in total

1.  Engineering and visualization of bacteria for targeting infarcted myocardium.

Authors:  Uyenchi N Le; Hyung-Seok Kim; Jin-Sook Kwon; Mi Yeon Kim; Vu H Nguyen; Sheng Nan Jiang; Byeong-Il Lee; Yeongjin Hong; Myung Geun Shin; Joon Haeng Rhee; Hee-Seung Bom; Youngkeun Ahn; Sanjiv S Gambhir; Hyon E Choy; Jung-Joon Min
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

Review 2.  Gene delivery technologies for cardiac applications.

Authors:  M G Katz; A S Fargnoli; L A Pritchette; C R Bridges
Journal:  Gene Ther       Date:  2012-03-15       Impact factor: 5.250

Review 3.  Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria.

Authors:  P Iyngkaran; M Thomas
Journal:  Clin Med Insights Cardiol       Date:  2015-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.